Roche's acquisition of Poseida Therapeutics (PSTX) for $1.5B joins the growing trend of cell therapies in M&A activities. Check out my review of this deal.
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic ...
Researchers studied the cumulative incidence and associated risk factors of keratinocyte carcinomas among patients who are survivors of childhood cancer.